308 related articles for article (PubMed ID: 25641006)
1. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
2. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
4. [Myocardial infarction: Role of new antiplatelet agents].
Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
6. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the pharmacological profiles of prasugrel and ticagrelor assessed by platelet aggregation, thrombus formation and haemostasis in rats.
Sugidachi A; Ohno K; Ogawa T; Jakubowski J; Hashimoto M; Tomizawa A
Br J Pharmacol; 2013 May; 169(1):82-9. PubMed ID: 23347039
[TBL] [Abstract][Full Text] [Related]
8. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
9. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology.
Clemmensen P; Dridi NP; Holmvang L
Cardiovasc Drugs Ther; 2013 Jun; 27(3):239-45. PubMed ID: 23380983
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study.
Bernlochner I; Mayer K; Orban M; Morath T; Jaitner J; Rössner L; Gross L; Laugwitz KL; Kastrati A; Sibbing D
Platelets; 2016 Dec; 27(8):796-804. PubMed ID: 27275651
[TBL] [Abstract][Full Text] [Related]
11. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity.
Lhermusier T; Lipinski MJ; Tantry US; Escarcega RO; Baker N; Bliden KP; Magalhaes MA; Ota H; Tian W; Pendyala L; Minha S; Chen F; Torguson R; Gurbel PA; Waksman R
Am J Cardiol; 2015 Mar; 115(6):716-23. PubMed ID: 25728845
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
[TBL] [Abstract][Full Text] [Related]
14. P2Y12 platelet inhibition in clinical practice.
Damman P; Woudstra P; Kuijt WJ; de Winter RJ; James SK
J Thromb Thrombolysis; 2012 Feb; 33(2):143-53. PubMed ID: 22183178
[TBL] [Abstract][Full Text] [Related]
15. Randomized Comparison of Oral P2Y
Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C
JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Wijeyeratne YD; Joshi R; Heptinstall S
Expert Rev Clin Pharmacol; 2012 May; 5(3):257-69. PubMed ID: 22697589
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP;
Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698
[TBL] [Abstract][Full Text] [Related]
18. The platelet P2Y₁₂ receptor for adenosine diphosphate: congenital and drug-induced defects.
Cattaneo M
Blood; 2011 Feb; 117(7):2102-12. PubMed ID: 20966167
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment platelet reactivity contribution to residual, post-treatment platelet reactivity in prasugrel-treated and ticagrelor-treated patients.
Alexopoulos D; Xanthopoulou I; Davlouros P; Tsigkas G; Damelou A; Theodoropoulos KC; Gkizas V; Hahalis G
J Thromb Haemost; 2013 Feb; 11(2):381-4. PubMed ID: 23216658
[No Abstract] [Full Text] [Related]
[Next] [New Search]